Table 2.
Survival analyses of overall survival for extremity liposarcoma patients
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| P | HR | 95.0% CI | P | ||
| Age | |||||
| < 65 | Reference | Reference | |||
| 65–76 | < 0.001 | 1.91 | 1.41–2.58 | < 0.001 | |
| > 76 | < 0.001 | 5.64 | 4.23–7.53 | < 0.001 | |
| Tumor size | |||||
| < 11.1 | Reference | Reference | |||
| 11.1–23.5 | 0.022 | 1.69 | 1.29–2.22 | < 0.001 | |
| > 23.5 | < 0.001 | 2.52 | 1.77–3.57 | < 0.001 | |
| Race | |||||
| Black | Reference | ||||
| Other | 0.426 | ||||
| White | 0.668 | ||||
| Sex | |||||
| Female | Reference | Reference | |||
| Male | 0.002 | 1.43 | 1.11–1.84 | 0.006 | |
| Histological type | |||||
| Liposarcoma, NOS | Reference | ||||
| Liposarcoma, well differentiated | 0.001 | ||||
| Myxoid liposarcoma | 0.327 | ||||
| Round cell liposarcoma | 0.005 | ||||
| Pleomorphic liposarcoma | < 0.001 | ||||
| Mixed liposarcoma | 0.256 | ||||
| Fibroblastic liposarcoma | 0.951 | ||||
| Dedifferentiated liposarcoma | < 0.001 | ||||
| AJCC | |||||
| I/II | Reference | ||||
| III/IV | < 0.001 | ||||
| T | |||||
| T1 | Reference | ||||
| T2 | 0.273 | ||||
| N | |||||
| N0 | Reference | ||||
| N1 | 0.063 | ||||
| M | |||||
| M0 | Reference | Reference | |||
| M1 | < 0.001 | 4.97 | 2.92–8.46 | < 0.001 | |
| Surgery | |||||
| No | Reference | Reference | |||
| Yes | < 0.001 | 0.33 | 0.20–0.55 | < 0.001 | |
| Radiotherapy | |||||
| No | Reference | ||||
| Yes | < 0.001 | ||||
| Chemotherapy | |||||
| No | Reference | ||||
| Yes | < 0.001 | ||||
| Primary site | |||||
| Lower extremity | Reference | ||||
| Upper extremity | 0.730 | ||||
| Grade | |||||
| I | Reference | Reference | |||
| II | 0.312 | 1.83 | 1.22–2.74 | 0.004 | |
| III | < 0.001 | 4.90 | 3.53–6.80 | < 0.001 | |
| IV | < 0.001 | 5.85 | 4.27–8.02 | < 0.001 | |
HR Hazard ratio, CI Confidence interval, AJCC American Joint Committee on Cancer